Growth inhibition across pancreatic cancer cell lines
Cell-based study · 29 human pancreatic cancer cell lines [1]
Cell-count-based growth sensitivity varied widely; KRAS mutation presence alone did not distinguish response.
| Endpoint | Reported result | Reference |
|---|---|---|
| Growth inhibition in PANC 05.04 | IC50 0.0027 μM | [1] |
| Growth inhibition in MIAPACA-2 | IC50 0.0092 μM | [1] |
| Growth inhibition in YAP-C | IC50 5.0654 μM | [1] |
| Growth inhibition in CFPAC1 | IC50 8.5259 μM | [1] |
| Growth inhibition in PATU-8988T | IC50 >10 μM | [1] |
| Mutant versus wild-type KRAS growth-inhibition IC50 comparison | P value P = 0.5271 | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- 10 μM to 0.0001 μM, tenfold serial dilutions
- Exposure duration
- Treatment 24 h after seeding; cells counted 6 days after seeding (approximately 5 days of exposure)
- Method
- Cell counting with Coulter-Z1; percent generational inhibition relative to untreated cells
- Reported limits
- Vehicle and tested material supplier/form characterization are not specified in the retrieved methods. Individual IC50 uncertainty is not tabulated. Experiments performed at least twice, wells seeded in duplicate.
Methods and source locations
Compound reported in the paper: MEK162 (binimetinib); Compound label in the paper: MEK162
Reported experimental material; no current AdooQ lot validation or clinical efficacy inference.
Table 1; Figure 1A–C; Methods: Proliferation assays; Results: Association of specific KRAS mutations with sensitivity to MEK inhibition
Growth inhibition in PANC 05.04: Cell-count growth inhibition; Table 1 numerical value, units established by Figure 1A and assay concentration range — Table 1, PANC 05.04 row; Figure 1A caption
Growth inhibition in MIAPACA-2: Cell-count growth inhibition; Table 1 numerical value, units established by Figure 1A and assay concentration range — Table 1, MIAPACA-2 row; Figure 1A caption
Growth inhibition in YAP-C: Cell-count growth inhibition; Table 1 numerical value, units established by Figure 1A and assay concentration range — Table 1, YAP-C row; Figure 1A caption
Growth inhibition in CFPAC1: Cell-count growth inhibition; Table 1 numerical value, units established by Figure 1A and assay concentration range — Table 1, CFPAC1 row; Figure 1A caption
Growth inhibition in PATU-8988T: Cell-count growth inhibition; Table 1 numerical value, units established by Figure 1A and assay concentration range — Table 1, PATU-8988T row; Figure 1A caption
Mutant versus wild-type KRAS growth-inhibition IC50 comparison: Comparison of average IC50; wild-type n = 4, mutant n = 25 cell lines — Figure 1C and caption; Results: Association of specific KRAS mutations